Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia

Human Gene Therapy

Volumn 24, Issue 8, 2013, Pages 717-727

  Barrett, David M ^a   Liu, Xiaojun ^b   Jiang, Shuguang ^b   June, Carl H ^b   Grupp, Stephan A ^a   Zhao, Yangbing ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; MESSENGER RNA;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENE THERAPY; CONTROLLED STUDY; LEUKEMIA; MOUSE; NONHUMAN; SINGLE DRUG DOSE; STABLE EXPRESSION; XENOGRAFT;

ANIMALS; ANTIGENS, CD19; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA; MICE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RNA; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882410441     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.075     Document Type: Article

References (51)

1. Barrett, D.M., Seif, A.E., et al. (2011a). Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling. Blood 118, e112-e117.
2. Barrett, D.M., Zhao, Y., et al. (2011b). Treatment of advanced leukemia in mice with mRNA engineered T cells. Hum. Gene Ther. 22, 1575-1586.
3. Bleyer, W.A. (1985). Cancer chemotherapy in infants and children. Pediatr. Clin. North Am. 32, 557-574.
4. Bracci, L., Moschella, F., et al. (2007). Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13(2 Pt 1), 644-653.
5. Brentjens, R.J., Santos, E., et al. (2007). Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13(18 Pt 1), 5426-5435.
6. Brentjens, R., Yeh, R., et al. (2010). Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol. Ther. 18, 666-668.
7. Brentjens, R.J., Riviere, I., et al. (2011). Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 118, 4817-4828.
8. Brentjens, R.J., Davila, M.L., et al. (2013). CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5, 177ra38.
9. Brocker, T., and Karjalainen, K. (1998). Adoptive tumor immunity mediated by lymphocytes bearing modified antigenspecific receptors. Adv. Immunol. 68, 257-269.
10. Carpenito, C., Milone, M.C., et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. USA 106, 3360-3365.
11. Cooper, L.J., Al-Kadhimi, Z., et al. (2004). Development and application of CD19-specific T cells for adoptive immunotherapy of B cell malignancies. Blood Cells Mol. Dis. 33, 83-89.
12. Cui, Y., Zhang, H., et al. (2009). Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 114, 3831-3840.
13. Elkin, G., Prigozhina, T.B., et al. (2004). Prevention of diabetes in nonobese diabetic mice by nonmyeloablative allogeneic bone marrow transplantation. Exp. Hematol. 32, 579-584.
14. Eshhar, Z., Waks, T., et al. (1993). Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc. Natl. Acad. Sci. USA 90, 720-724.
15. Gammon, S.T., Leevy, W.M., et al. (2006). Spectral unmixing of multicolored bioluminescence emitted from heterogeneous biological sources. Anal. Chem. 78, 1520-1527.
16. Grupp, S.A., Kalos, M., et al. (2013). Chimeric antigen receptormodified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368, 1509-1518.
17. Horowitz, M.M., Gale, R.P., et al. (1990). Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75, 555- 562.
18. Imai, C., Mihara, K., et al. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676-684.
19. Kalos, M., Levine, B., et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci. Transl. Med. 3, 95ra73.
20. Kershaw, M.H., Westwood, J.A., et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12(20 Pt 1), 6106-6115.
21. Kochenderfer, J.N., Yu, Z., et al. (2010a). Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875-3886.
22. Kochenderfer, J.N., Wilson, W.H., et al. (2010b). Eradication of Blineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099-4102.
23. Lee, J.C., Hayman, E., et al. (2011). In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71, 2871-2881.
24. Levine, B., Bernstein, W., et al. (1997). Effects of CD28 costimulation on long-term proliferation of CD4 + T cells in the absence of exogenous feeder cells. J. Immunol. 159, 5921-5930.
25. Li, L., Liu, L.N., et al. (2010). Expression of chimeric antigen receptors in natural killer cells with a regulatory-compliant non-viral method. Cancer Gene Ther. 17, 147-154.
26. Lu, Y., Douraghy, A., et al. (2009). Spectrally resolved bioluminescence tomography with the third-order simplified spherical harmonics approximation. Phys. Med. Biol. 54, 6477-6493.
27. Maher, J., Brentjens, R.J., et al. (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCR zeta/CD28 receptor. Nat. Biotechnol. 20, 70-75.
28. Malone, R.W., Felgner, P.L., et al. (1989). Cationic liposomemediated RNA transfection. Proc. Natl. Acad. Sci. USA 86, 6077-6081.
29. Mao, Y. (2011). Dynamics studies of luciferase using elastic network model: how the sequence distribution of luciferase determines its color. Protein Eng. Des. Sel. 24, 341-349.
30. Marktel, S., Magnani, Z., et al. (2003). Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 101, 1290-1298.
31. Masters, J.R., Thomson, J.A., et al. (2001). Short tandem repeat profiling provides an international reference standard for human cell lines. Proc Natl Acad Sci USA 98, 8012-8017.
32. Mezzanotte, L., Que, I., et al. (2011). Sensitive dual color in vivo bioluminescence imaging using a new red codon optimized firefly luciferase and a green click beetle luciferase. PLoS One 6, e19277.
33. Milone, M.C., Fish, J.D., et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453-1464.
34. Morgan, R.A., Yang, J.C., et al. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843-851.
35. Nadler, L.M., Anderson, K.C., et al. (1983). B4, a human B lymphocyte-associated antigen expressed on normal, mitogenactivated, and malignant B lymphocytes. J. Immunol. 131, 244-250.
36. Nakajima, Y., Kimura, T., et al. (2005). Multicolor luciferase assay system: one-step monitoring of multiple gene expressions with a single substrate. Biotechniques 38, 891-894.
37. Nienhuis, A.W., Dunbar, C.E., et al. (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol. Ther. 13, 1031- 1049.
38. Pinthus, J.H., Waks, T., et al. (2004). Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J. Clin. Invest. 114, 1774-1781.
39. Porter, D.L., Levine, B.L., et al. (2011a). Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725-733.
40. Pule, M.A., Savoldo, B., et al. (2008). Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat. Med. 14, 1264-1270.
41. Rabinovich, P.M., Komarovskaya, M.E., et al. (2009). Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum. Gene Ther. 20, 51-61.
42. Savoldo, B., Ramos, C.A., et al. (2011). CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J. Clin. Invest. 121, 1822-1826.
43. Shimasaki, N., Fujisaki, H., et al. (2012). A clinically adaptable method to enhance the cytotoxicity of natural killer cells against B-cell malignancies. Cytotherapy 14, 830-840.
44. Tafreshi, N., Sadeghizadeh, M., et al. (2008). Site-directed mutagenesis of firefly luciferase: implication of conserved residue (s) in bioluminescence emission spectra among firefly luciferases. Biochem. J. 412, 27-33.
45. Teachey, D.T., Obzut, D.A., et al. (2006). The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood 107, 1149-1155.
46. Till, B.G., Jensen, M.C., et al. (2008). Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 112, 2261-2271.
47. Till, B.G., Jensen, M.C., et al. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119, 3940-3950.
48. Yu, A.L., Gilman, A.L., et al. (2010). Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N. Engl. J. Med. 363, 1324-1334.
49. Zhao, Y., Zheng, Z., et al. (2005). Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines. J. Immunol. 174, 4415-4423.
50. Zhao, Y., Zheng, Z., et al. (2006). High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. Mol. Ther. 13, 151-159.
51. Zhao, Y., Moon, E., et al. (2010). Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. 70, 9053-9061.